IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Cheever et al.

Serial No.: 09/493,480 Art Unit: 1643

Filing Date: January 28, 2000 Examiner: A. Holleran

[] Copies of the references were submitted in parent application

For: HER-2/Neu Fusion Proteins

[X] Copies of the references are enclosed

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

(37 CFR 1.98(d))

INFORMATION DISCLOSURE STATEMENT

Serial No. ______.

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

A copy of the International Search Report which issued on International Application No.

Search Report have been
within three e national stage action on the
iled before the nued
er three month al stage as set e first Office date of either:
formation fice in a g of this
submission of
al stage are first Of clate of eigenvalues. Cormation fice in a growth of this

Atty. Docket No. CRX113US

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.
	In acco	ordance with the requirements of 37 CFR 1.97(d):
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
		charge any required fees to Deposit Account No.07-1392. icate copy of this paper is attached.

Respectfully Submitted,

/Virginia G. Campen/ Virginia G. Campen Attorney of Record Registration No. 37,092

Date: 22 June 2006 Customer No. 23347 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1012 Facsimile: (919) 483-7988